Multinational Patterns of Second-line Anti-hyperglycemic Drug Initiation Across Cardiovascular Risk Groups

A Federated Pharmacoepidemiologic Evaluation in LEGEND-T2DM

Lovedeep Singh Dhingra, MBBS
CarDS Lab, Yale School of Medicine
(for the LEGEND-T2DM investigators)
Type 2 Diabetes Mellitus (T2DM) → Metformin → 1st line agent

- Elevated blood sugar
- Blood sugar still elevated

2nd line agents

- DPP4 inhibitors (DPP4i)
- Sulfonylureas (SU)
- GLP-1 Receptor Agonists (GLP-1 RA)
- SGLT2 inhibitors (SGLT2i)

Cardiovascular outcome RCTs

- Neutral effect
- Not evaluated
- Reduced cardiovascular risk
- Reduced cardiovascular risk

MI, Death, Heart Failure
Multinational Serial Cross-sectional Study
2011-2021

US National Databases
- IBM MarketScan® Commercial Claim and Encounters Data (CCAE)
- IBM Health MarketScan® Multistate Medicaid Database (Medicaid)
- IBM Health MarketScan® Medicare Supplemental and Coordination of Benefits Database (Medicare)
- Optum Clininformatics Extended Data Mart - Date of Death (Optum CEDM)
- Optum© de-identified Electronic Health Record Dataset (Optum EHR)
- US Open Claims

US Health System Databases
- Columbia University Irving Medical Center
- Johns Hopkins Medicine
- Stanford Medicine
- Department of Veterans Affairs Healthcare System
Inclusion Criteria

- Age ≥18 years
- Presence of T2DM
- Prior metformin use
- No prior second-line anti-hyperglycemic agent use

Outcomes

- Calendar-year trends for proportionate initiation 2\textsuperscript{nd} line agents
- Comparison of annualized change in initiation of GLP-1 RA and SGLT2i in patients with and without CVD

Exposures

- Presence of established cardiovascular disease
- Calendar Years
Proportionate Incident Use of Second-line Anti-hyperglycemic Agents in 2021
GLP-1 RA Uptake in Patients with Established CVD

- Initiation of GLP-1 RAs increased to 20-25% across most US populations
- Initiation was <5% in the VA
- Initiation was low across non-US databases, reaching a maximum of 14% in France in 2021
SGLT2i Uptake in Patients with Established CVD

- Initiation of SGLT2is increased to ~35% across US populations
- In the non-US databases, the initiation of SGLT2is was higher in most databases, reaching up to 54% in Scotland in 2021
- In France, the initiation was lower, reaching only to 6% in 2021
## Slope Interaction for Annualized Change in Cardioprotective Agent Initiation in Patients with and without CVD (2016-2021)

### Representative Examples for GLP-1 RA Initiation

<table>
<thead>
<tr>
<th>Data Source</th>
<th>With-CVD Slope</th>
<th>Without-CVD Slope</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCAE</td>
<td>0.019 (0.011 to 0.026)</td>
<td>0.068 (0.037 to 0.099)</td>
<td>0.003</td>
</tr>
<tr>
<td>Columbia</td>
<td>0.017 (0.011 to 0.023)</td>
<td>0.031 (0.016 to 0.047)</td>
<td>0.040</td>
</tr>
<tr>
<td>Medicare</td>
<td>0.051 (0.009 to 0.092)</td>
<td>0.051 (0 to 0.102)</td>
<td>0.986</td>
</tr>
<tr>
<td>France</td>
<td>0.003 (0.001 to 0.006)</td>
<td>0.014 (0.004 to 0.023)</td>
<td>0.024</td>
</tr>
<tr>
<td>Spain</td>
<td>0.003 (-0.001 to 0.006)</td>
<td>0.010 (0.001 to 0.019)</td>
<td>0.062</td>
</tr>
</tbody>
</table>

### Representative Examples for SGLT2i Initiation

<table>
<thead>
<tr>
<th>Data Source</th>
<th>With-CVD Slope</th>
<th>Without-CVD Slope</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCAE</td>
<td>0.014 (0.006 to 0.023)</td>
<td>0.035 (0.011 to 0.059)</td>
<td>0.053</td>
</tr>
<tr>
<td>Columbia</td>
<td>0.037 (0.022 to 0.052)</td>
<td>0.024 (0.013 to 0.034)</td>
<td>0.074</td>
</tr>
<tr>
<td>Medicare</td>
<td>0.092 (0.011 to 0.172)</td>
<td>0.056 (0.008 to 0.104)</td>
<td>0.325</td>
</tr>
<tr>
<td>France</td>
<td>0.001 (-0.001 to 0.003)</td>
<td>0.005 (-0.001 to 0.011)</td>
<td>0.132</td>
</tr>
<tr>
<td>Spain</td>
<td>0.033 (0.016 to 0.049)</td>
<td>0.065 (0.017 to 0.112)</td>
<td>0.115</td>
</tr>
</tbody>
</table>
Conclusion

• LEGEND-T2DM is the largest multinational pharmacoepidemiology study of anti-hyperglycemic therapy.

• Despite increased uptake, there is vast variation in use of cardioprotective therapies uses across populations with CVD.

• The uptake of these has been lower in the US, relative to other countries, particularly in patients with established CVD.

• Lack of selective use in CVD patients despite specific benefit in the population.
Thank you for your attention!

Co-investigators

- Rohan Khera
- Marc A Suchard
- Arya Aminorroaya
- Kelly Li
- Harlan M Krumholz
- George Hripcsak
- Jin Zhou
- Martijn J Schuemie
- Yuan Lu
- Anna Ostropolets
- RuiJun Chen
- Tara Anand
- Faaizah Arshad
- Seng Chan You
- Patrick B Ryan
- David A. Dorr
- Clair Blacketer
- Fan Bu
- Thomas Falconer
- Wallis CY Lau
- Yuntian Liu
- Paul Nagy
- Daniel R. Morales
- Talita Duarte-Salles
- Kenneth KC Man
- Evan Minty
- Mary Grace Bowring
- Michael Cook
- Nestoras Mathioudakis
- Akihiko Nishimura
- Carlen Reyes
- Andrea Pistillo
- Nicole Pratt
- Eric Yuk Fai Wan
- Jianxiao Yang
- Can Yin
- Sarah Seager
- Scott L DuVall
- Tina E French
- Elizabeth E Hanchrow
- Michael E Matheny
- Michael E McLemore
- Katherine R Simon

Correspondence to:

Rohan Khera, MD, MS
rohan.khera@yale.edu, @rohan_khera

Marc A Suchard, MD, PhD
msuchard@ucla.edu, @suchard_group

Disclosures:
cards-lab.org/legend-t2dm-disclosures